Metropolis Healthcare shares climbed approximately 4% on August 28, 2026, following a positive report from ICICI Securities. The brokerage set a target price of Rs 675, citing strong earnings growth prospects through fiscal 2028 and improved operational efficiency.
Metropolis Healthcare shares traded higher by nearly 4% on August 28, 2026, as investor sentiment improved following a bullish note from ICICI Securities. The brokerage firm maintained its 'Buy' rating on the diagnostics company, setting a target price of Rs 675 based on expectations of sustained financial performance.
ICICI Securities anticipates that the company will achieve an earnings compound annual growth rate (CAGR) of 29% between fiscal 2026 and fiscal 2028. This outlook is supported by a projected 15% revenue growth over the same period. The analysts expect this growth to be driven by a combination of higher testing volumes, estimated to rise by 9% to 10%, and a move toward more valuable testing mixes.
In recent corporate developments, the company transferred its External Quality Assessment Services (EQAS) division to its subsidiary, Metropolis Quality Solutions Private Limited. This move is part of the company's efforts to streamline its operations as it manages its diagnostic network.
Looking at profitability, the brokerage projects that the company’s EBITDA margins could expand by approximately 230 basis points through fiscal 2028. Such an improvement would suggest that the company is successfully focusing on operational efficiency and managing costs effectively, which are crucial for maintaining profitability in the competitive Indian diagnostic industry.
While the outlook is positive, the diagnostics sector faces several challenges. Analysts highlighted that increased market competition is a key factor that could pressure future results. Furthermore, unexpected regulatory hurdles or difficulties in successfully executing network expansion plans could impact the company's performance. As the company continues its growth strategy, investors may monitor how effectively management handles these operational risks and whether margin improvements remain consistent with these projections in upcoming quarterly results.